Rocket Pharmaceuticals (RCKT) Total Liabilities (2014 - 2026)

Rocket Pharmaceuticals (RCKT) has 13 years of Total Liabilities data on file, last reported at $47.4 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities fell 19.62% year-over-year to $47.4 million; the trailing twelve-month figure through Mar 2026 stood at $47.4 million (down 19.62% YoY), and the FY2025 full-year result was $53.2 million, down 17.43% from the prior year.
• Total Liabilities fell to $47.4 million in Q1 2026, from $53.2 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $73.8 million in Q4 2023 to a low of $42.5 million in Q1 2022.
• A 5-year average of $57.3 million and a median of $57.9 million in 2024 frame the typical range for Total Liabilities.
• Peak annual rise in Total Liabilities reached 46.87% in 2022, while the deepest fall reached 55.92% in 2022.
• Tracing RCKT's Total Liabilities over 5 years: stood at $62.1 million in 2022, then grew by 18.75% to $73.8 million in 2023, then decreased by 12.61% to $64.5 million in 2024, then fell by 17.43% to $53.2 million in 2025, then decreased by 11.01% to $47.4 million in 2026.
• Business Quant data shows RCKT's Total Liabilities at $47.4 million in Q1 2026, $53.2 million in Q4 2025, and $54.4 million in Q3 2025.